Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change.

Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump administration could shape healthcare in the years to come. In this episode, Glenn Hunzinger, Jenny Colapietro, and guests Kelly Griffin, Phil Sclafani, and Ruchita Kewalramani break down the potential implications of proposed government healthcare cuts, tariff policy and agency workforce reductions, along with the growing role of AI in the industry. They also discuss how pharma, medtech, payers and providers can stay ahead amidst the uncertainty. Discussion highlights:

• Proposed funding cuts to major government healthcare programs like Medicare, Medicaid, and NIH could significantly disrupt access, affordability, and service delivery across the healthcare landscape.
• Workforce reductions at federal agencies like the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Health and Human Services (HHS) may slow drug approvals, diminish oversight, and impact public health standards.
• New and evolving tariff policies are creating cost pressures across pharmaceutical and medtech supply chains, with potential downstream impacts on pricing, R&D, and patient access.
• The rapid adoption of AI in healthcare is creating new opportunities across diagnostics, R&D, and operations, while also raising concerns around governance and data privacy.
• To stay ahead, industry leaders must assess risks, strengthen agility, and uncover opportunities to innovate in today’s dynamic environment.

Speakers:

Kelly Griffin, Director, Health Policy Intelligence Institute, PwC
Ruchita Kewalramani, Partner, Health Services PwC
Phil Sclafani, Partner, Pharma & Life Sciences, PwC
Glenn Hunzinger, Partner, Health Industries Leader, PwC
Jenny Colapietro, Principal, Consulting Commercial Leader, PwC

Linked materials:

Health Policy and Intelligence Institute

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights:

• Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction Act
• Examining heightened competition across therapeutic areas and the rapid emergence of rival treatments affecting market economics
• Highlighting the necessity for bold strategic moves and critical capabilities, including AI innovation, portfolio optimization, strategic partnerships, and comprehensive risk management
• Addressing disruptive forces such as geopolitical uncertainty, tariff impacts, and the rise of global innovation influencing pharmaceutical markets
• Emphasizing the urgency for pharma leaders to embrace innovation and transformative strategies to improve healthcare affordability, accessibility, and quality

Speakers:

Greg Rotz, Pharmaceutical & Life Sciences Leader,PwC
Glenn Hunzinger, Health Industries Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:

Next in pharma 2025: The future is now

Pharmaceutical and life sciences: US Deals 2025 outlook

President Donald J. Trump’s healthcare agenda

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as PwC specialists discuss the 2025 healthcare outlook, reflecting on 2024’s significant events and exploring how payers and providers can navigate rising costs, scrutiny, AI advances, and policy shifts with resilience and adaptability.

Topics include:

• Medicare and Medicaid drive industry growth amid rising competition, market exits, M&A, AI adoption, and policy challenges.
• AI's potential to enhance healthcare delivery, improve workforce management, and optimize patient care.
• The care-at-home market is growing rapidly, driven by demand and cost efficiency, but sustainability remains a challenge.
• Encouragement for healthcare organizations to adapt and innovate in response to policy shifts and technological advancements.

Speakers:
Thom Bales, Health Services Leader, PwC
Alena Taylor, Principal, PwC
Ruchita Kewalramani, Principal, PwC
Glenn Hunzinger, Health Industries Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:

• Next in Health: The 2025 Outlook for Health Services: https://www.pwc.com/us/en/industries/health-industries/library/healthcare-trends.html
• Health Policy and Intelligence Institute: https://www.pwc.com/us/en/industries/health-industries/health-policy-and-intelligence-institute.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in to listen as PwC’s leaders Roel van den Akker and Nick Donkar provide insights into the 2024 deals landscape and offer a preview of what lies ahead. Topics include:

Key topics include:

• A look back at M&A activity in health industries in 2024
• The challenges and potential impediments that could affect deal volumes in the coming year
• How artificial intelligence and tech innovations are reshaping the volume and nature of healthcare transactions
• Key trends and developments to watch for with emphasis on growth, strategic assessments and regulatory factors

Speakers:
Roel van den Akker, Pharmaceutical and Life Sciences Deals Leader, PwC
Nick Donkar, Health Services Deals Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:

• https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as authors of PwC's U.S. Healthcare Climate Survey discuss key findings and provide insights into understanding healthcare organizations' responses to climate change, the integration of climate strategies, and the challenges faced in implementation.

Key topics include:

• The survey's background, focus, and objectives that address the prioritization of climate strategies by healthcare organizations in response to climate change impacts
• Differences in climate strategy approaches across sectors, reveals significant disparities in priorities and operational needs amongst payers, providers, pharmaceutical, and medtech companies
• Key statistics and insights on organizational behavior and perceptions related to climate strategy integration, sustainability, and the impact on human health
• Considerations for healthcare stakeholders to enhance climate strategy implementation and address the evolving needs of diverse communities affected by climate change

Speakers:
Mackenzie Daly, Partner, PwC
Stacie Gitkin, Director, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:
https://www.pwc.com/us/en/industries/health-industries/library/impact-of-climate-change-on-human-health.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Tune in as authors of PwC's U.S. Healthcare Consumer Insights and Engagement Survey discuss key findings and provide insights into understanding consumer concerns around healthcare costs, the adoption of tech-enabled healthcare, trust in the healthcare system and how we can take action.

Key topics include:

• The survey's background, focus and objectives that will address ongoing consumer concerns and distrust in the healthcare system
• Generational and financial differences reveal significant disparities in healthcare experiences and engagement amongst various age groups
• Notable key statistics and insights on consumer behavior and perceptions related to trust, affordability, delayed care and digital health across the health ecosystem
• Considerations for healthcare stakeholders to enhance care delivery and to address the evolving needs of diverse patient populations

Speakers:
Thom Bales, Health Services Leader, PwC
Keith Fengler, Customer Service and Channels Lead, PwC,
Omar Chane, Principal, PwC.
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:
https://www.pwc.com/us/en/industries/health-industries/library/healthcare-consumer-insights-survey.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

How can medtech companies drive growth in today's market? Tune in as PwC specialists return to share key insights and strategies to help medtech companies invest in the capabilities required to compete in the future while aiming to exceed near-term expectations for growth and margin improvement.

Key topics include:

• Challenges currently faced by medtech companies
• Reevaluating business models and new ways to play
• Driving returns on historical investments in technology by leveraging data and transforming legacy processes
• Embracing a “high-tech” mindset to enable change and creating a culture of empowered decision makers
• Unlocking value through strategic M&A

Speakers:
James Woods, Principal, PwC
Kevin McLellan, Principal, Strategy&, PwC
Luna Corbetta, Principal, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Materials:
https://www.pwc.com/us/en/industries/health-industries/medical-technology/medtech-industry-insights.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

What can the health industry expect from a second Trump administration? Tune in to hear what executives should watch over the next few months and years to come.

Key topics include:

• President-elect Trump's healthcare agenda and his focus on deregulation, flexibility and choice, and accessibility
• Potential implications for medicare, the ACA and IRA drug negotiations
• What to watch in the first 100 days

Speakers:
Kelly Griffin, Director, Health Policy and Intelligence Institute
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:
https://www.pwc.com/us/en/industries/health-industries/library/election-2024-trump-health-agenda.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.